VNRX - VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript
2024-03-26 12:43:06 ET
VolitionRx Limited (VNRX)
Q4 2023 Results Conference Call
March 26, 2024 08:30 AM ET
Company Participants
Louise Batchelor - Chief Marketing and Communications Officer
Cameron Reynolds - President and Group Chief Executive Officer
Terig Hughes - Group Chief Financial Officer
Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary
Andrew Retter - Medical Consultant, Volition
Conference Call Participants
Tim Moore - EF
Ilya Zubkov - Freedom Broker
Bruce Jackson - The Benchmark Company
Steven Ralston - Zacks
Presentation
Operator
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full Year 2023 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. [Operator Instructions]. This conference call is being recorded today, March 26, 2024.
I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.
Louise Batchelor
Thank you, and welcome, everyone to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us.
Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission.
We do not undertake an obligation to update any forward-looking statements made during the course of this call. I am joined today by Mr. Cameron Reynolds, President and Group Chief Executive Officer, Mr. Terig Hughes, Group Chief Financial Officer Doctor, Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary and Dr. Andrew Retter, currently Medical Consultant to Volition, which has recently announced due to join Volition n the role of Chief Medical Officer in April 2024.
During the call, we will cover Volition's financial and operating results for the fourth quarter and full fiscal year of 2023, along with a discussion of our recent activities and upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session....
VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript